The Role of Risk Analysis in Expanding Business Activities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Role of Risk Analysis in Expanding Business Activities
Risk management is essential in any successful outsourcing partnership. The author outlines the steps toward identifying, understanding, and controlling risk in key manufacturing areas.


Pharmaceutical Technology


The assessment must differentiate the areas of higher risk (threats) from those that represent chances for improvement (opportunities). The operative tools necessary to identify risk areas are then finally presented to define the value (risk analysis) and to attribute the level of gravity and acceptance for business (risk assessment), the possible need for remedial actions, and the resolution time and responsibilities (action–remediation plan).


Figure 2
Weight-up. Risk weight-up considers the effect and probability of threats and opportunities enumerated in the risk identification phase; these can be weighted using the different levels shown in each quadrant in Figure 2. The levels are defined as follows: very high (VH), high (H), medium (M), low (L), and very low (VL). Because the defined levels are five in the ordinate and five in the abscissa of each quadrant, the worst-case risk is associated with the couple VH–VH (5 5 = 25). Similarly, the best-case risk is associated with the couple VL–VL (1 1 = 1).

The quadrants are highlighted in colors corresponding to probability and impact-level combination. The yellow areas are where the risk is acceptable for threats and opportunities. The red and pink areas are associated with the unacceptable risk for threats and opportunities.

For example, if you must transfer an industrial process in an emerging country in which partner knowledge (or experience, etc.) may be very low and the cost is very low, then the evaluation of the risk is:
threat: impact VH(5) probability VH(5) = risk 25
opportunity:impact VL(1) probability VL(1) = risk 1


Example of a supplier evaluation questionnaire
Therefore, there is a big threat to transfer the industrial process, with a very low confidence level and a very big economic opportunity. In this case, management must decide whether the economic opportunity is acceptable while considering the risk associated with the partner's inexperience or whether it is better to partner with another more knowledgeable service provider for an acceptable increase of cost. In this alternative case, the threat risk may be considerably less, and the opportunity could be less interesting.

Essential elements of a preliminary evaluation protocol

The evaluation of a selected partner may involve several financial and industrial aspects (see sidebar, "Example of a supplier's evaluation questionnaire"). The evaluation should also contain information about the following:

  • Identification of the designated contact person
  • Date of the company's foundation
  • Company turnover during the past three years and turnover percentage connected to exportation(availability of the company's financial statements)
  • Number of employees, their turnover and distribution on the basis of the competence areas (e.g., logistics, administration, production, control)
  • Organization chart, roles, and responsibilities
  • Analysis of the processes and activities performed internally and externally
  • Main products and customers and their percentage division
  • Proprietary products registrations
  • Problems from natural disasters (earthquakes, typhoons) in the contract manufacturing areas and protective actions
  • Dimension and layout of the property (covered and open warehouses, production, offices, etc.), including their building standards, age, and possibility of expansion
  • Management of main energy resources (electricity, water, etc.)
  • Protection of the area against damages and fire
  • Protection from intrusions and terrorism
  • Protection and backup of critical and reserved information
  • Production organization (e.g., number of shifts)
  • Costs for developing starting materials into the finished product
  • Saturation level of the most important systems (free capacity) and their age
  • Activities automation and information-technology levels
  • Existence of management procedures for major good manufacturing practice processes (e.g., review and release of the batches, complaints, market's traceability and recall, deviations, changes, staff education, and training)
  • Manufacturing management and product control (e.g., written specifications defined for each product and its components, equipment, and critical validated processes; written analytical methods; batch documentation; and functions dedicated to the planning of productive activities and to materials stocks)
  • Main customers, their qualification, and reliability
  • Materials management and its status (e.g., conditions of preservation, quarantine status approved and rejected, cleanliness of the areas, shipment conditions and related documentation)
  • Local authorizations, licenses, and voluntary certifications (ISO, etc.)
  • Preventive-maintenance programs
  • Calibration and validation scheduling for control devices and critical equipment
  • Materials control and approval levels of the various stages of the manufacturing cycle (e.g., raw materials and packaging materials, bulk and finished product).
  • Management of company safety, contingency, and emergency plans
  • Control of emissions in the atmosphere and of environmental compatibility
  • Company politics in human resources (e.g., no discrimination, equal opportunities, rights, and duties).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here